Citius Pharmaceuticals (CTXR) Misses Q3 EPS by 37c

Citius Pharmaceuticals (NASDAQ: CTXR) reported Q3 EPS of ($0.34), $0.37 worse than the analyst estimate of $0.03. Revenue for the quarter came in at $1.5 million versus the consensus estimate of $12.52 million.

For earnings history and earnings-related data on Citius Pharmaceuticals (CTXR) click here.

You May Also Be Interested In

• Citi upgrades O-I Glass to Buy with $9 price target, opens 90-Day upside catalyst watch
• ScanSource (SCSC) Tops Q4 EPS by 32c
• BMO Capital Starts Skyworks Solutions (SWKS) at Market Perform